![](https://r1f5c3.p3cdn1.secureserver.net/wp-content/uploads/2023/07/Scorpius_Logo_Hoz_FinaBio.jpeg?time=1721822922)
Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197
Fina Biosolutions has selected Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197conjugate vaccine carrier protein.
The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, scale-up, and cGMP bulk drug substance manufacturing of CRM197, a genetically detoxified diphtheria toxin widely used in conjugate vaccines. FinaBio markets their CRM197 under the tradename EcoCRM®.
Read complete press release.